Key Takeaways
- Volume-led quarter, demand cracks appear: Revenue grew ~15–20% YoY by volume, with ~25% from raw material price pass-through, but management flagged a "very, very severe" slowdown in domestic dyestuff and softness in textiles and FMCG.
- EBITDA protected, but forex and one-offs distort optics: Normalizing for a ~₹32 crore shortfall fee in the base quarter, YoY EBITDA growth was closer to 30%; a ~₹30 crore MTM forex loss on ECBs hit PBT.
- FY24 is the operating leverage story: Management expects a substantial EBITDA jump in FY24 as long-term contracts ramp to 70–80% utilization and most fixed costs are absorbed in FY23, so incremental gross profit largely translates to EBITDA.
- Nitric acid strategy is the big CAPEX call: A 225–250 TPD concentrated nitric acid plant is underway, and a ~₹500 crore-plus weak nitric acid plant from ammonia is under evaluation; debt-to-equity could move to 0.7–0.9x if that proceeds alongside ongoing expansions.
- What to watch next quarter: Whether management revises full-year guidance after Q2, the pace of dyestuff and textile demand recovery, and any decision on the backward-integrated nitric acid plant.
Demand Environment
- Domestic weakness concentrated in a few sectors: Textiles, FMCG and dyestuff saw a slowdown, with dyestuff described as "very, very severe"; these segments normally represent 10–20% of sales, and the company re-juggles its product portfolio when a segment is down.
- Export demand holding up: Polymers, agro and pharma export markets have not been materially impacted by the demand slowdown; no feedback from European customers that the energy crisis will hurt their demand, as their further value-addition steps are less energy-intensive.
- Raw material supply easing: Short supply of nitric acid impacted the business but the situation eased in June 2022; H2 FY23 may still see issues, but FY24 should not have significant shortages once new domestic capacity comes online.
- PDA volumes down on product mix: Nitrotoluene volumes were better, but PDA volumes declined due to product mix impact from nitric acid availability constraints.
Rajendra Gogri: "In the Dyestuff sector - you might have seen in the news also, that there is a significant slowdown in the Indian dyestuff market and it is very, very severe. Hopefully, things should start getting better in the next few months."
Long-Term Contracts & Volume Ramp-Up
- First contract trajectory: Utilization was around 25% in Q1, expected at 30–40% for FY23 overall and 50% in H2, reaching 70–80% by FY24 end; qualification quantities were given in Q1 and ramp-up is expected in H2.
- Second contract trajectory: Utilization progressively increasing, expected to reach 70–80% by FY24; first-year utilization around 40–50%, but structured so that even at lower top-line, EBITDA impact is limited.
- Third contract and NCB expansion: Underway, expected to be commissioned in the forthcoming quarter and to start contributing to revenues from FY24.
- Customer diversification: The first contract supplies qualification material to various customers across both domestic and export markets; discussions are ongoing for potential long-term tie-ups but nothing is finalized.
- More large contracts possible: Management sees potential for additional large, long-tenure contracts going forward, similar to the three already disclosed.
Rajendra Gogri: "Overall, the way it is structured, even the top line may be less, but at the EBITDA level, there will not be much impact linked to the capacity utilization."
Nitric Acid Strategy & CAPEX
- Concentrated nitric acid plant: Tied up with a technology partner for a 225–250 TPD unit to convert dilute nitric acid to concentrated; order placed, in detailed engineering, construction to start shortly, commissioning planned for Q4 FY24.
- Weak nitric acid plant under evaluation: Evaluating a comprehensive facility including own WNA plant from ammonia at an estimated cost of ₹500 crore-plus for 500 TPD; decision depends on long-term WNA availability, pricing, and whether the ammonia-based route makes cost sense.
- WNA plant utilization: Expected at 75–80% captive initially, moving to 100% captive as demand grows; not much intended for merchant sales.
- Debt implications: Debt-to-equity may move higher if the substantial nitric acid investment proceeds alongside ongoing expansions; management targets 0.7–0.9x on the higher side.
- Combined FY23–FY24 CAPEX: Approximately ₹3,000 crore over the two years combined; most construction happens in the October-to-June window to avoid heavy rains.
Rajendra Gogri: "If you're backward integrated then you are in-line with everybody because everybody has to source ammonia at global prices."
Margins & Operating Leverage
- Gross margin QoQ pressure: Increase in raw material costs drove the impact, with benzene moving from ₹77 to ₹94 and sulphur from ₹27 to ₹37.
- Cost pass-through largely successful: The company passed on cost pressure linked to raw material prices and utilities to customers, protecting absolute EBITDA; in pharma, most input and utility costs were passed on but some had to be absorbed.
- FY24 operating leverage thesis: A substantial part of fixed cost will be built in by FY23, so in FY24 incremental gross profit will virtually translate to EBITDA as volumes ramp on the long-term contracts.
- New product margin profile: The 90-odd products in the pipeline are likely to bring a margin profile of 25–30% beyond FY24; the chlorotoluene range will have almost 90% value-added products.
- Asset turns on new CAPEX: Expected to be lower, between 1–1.5x, because the new products are more value-added.
- Inventory gains and losses: Partly negated by lagged pricing in contracts: exports have a 2–3 month lag, domestic is month-to-month or 1–2 months.
Rajendra Gogri: "In the Chemicals segment, we expect a substantial jump in EBITDA in FY'24 and FY'25. Then the new project will start kicking in from FY'25 onwards."
Pharma Business & Demerger
- Pharma performance: Driven by continued high demand for key products, better volume trajectory from generic pharma companies and the Xanthine business; demand visibility remains positive across cardiovascular, anti-diabetic, anti-hypertensive, oncology and corticosteroid segments.
- USFDA audit at Dombivli: Conducted in June, raised 2 points under a 483; management is confident of addressing them and receiving an EIR soon, which would make Dombivli the third USFDA-approved facility.
- New API block commissioned: A new API block at the already-approved Tarapur facility was commissioned in early Q2.
- New greenfield pharma site: Land acquired near Dahej, in Atali, for setting up a new greenfield pharma site.
- Demerger update: NCLT hearings on the proposed demerger of the pharma business to Aarti Pharmalabs Limited concluded on 1 August 2022; the order is expected soon, and management will take up necessary action items to make the demerger effective immediately.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| First long-term contract utilization | Reach 70–80% utilization | By FY24 end |
| Second long-term contract utilization | Reach 70–80% plus utilization | By FY24 |
| Third long-term contract and NCB expansion | Commissioned and contributing to revenues | From FY24 |
| Concentrated nitric acid plant | 225–250 TPD plant commissioned | Q4 FY24 |
| Fixed cost absorption | Substantial part of fixed cost built in; no major increase thereafter | By FY23 end |
| Chemicals segment EBITDA | Substantial jump as volumes ramp | FY24 and FY25 |
| Guidance revision decision | Review full-year guidance after assessing Q2 demand | After Q2 |
| Debt-to-equity ceiling | Target 0.7–0.9x on the higher side if nitric acid investment proceeds | Ongoing |
| Combined CAPEX | ~₹3,000 crore | FY23 and FY24 combined |
Key Metrics
| Metric | Q1 FY23 |
|---|---|
| Revenue | ₹2,173 cr, up 45% YoY |
| EBITDA | ₹369 cr, up 18% YoY; normalized for ₹32 cr shortfall income in Q1 FY22, growth closer to 30% |
| Profit after tax | ₹189 cr, up 15% YoY |
| Mark-to-market forex impact on PBT | ₹30 cr negative impact, from ECB depreciation vs USD |
| Specialty Chemicals revenue | ₹1,766 cr, up 44% YoY |
| Specialty Chemicals EBIT | ₹250 cr, up 8% YoY; normalized for shortfall income, growth about 25% |
| Pharma revenue | ₹407 cr, up 48% YoY |
| Pharma EBIT | ₹76 cr, up 46% YoY |
| Revenue growth split | ~25% from raw material price increases, ~15–20% from volume growth |
| Export share | 46%, up from below 40% in Q4 FY22 |
| CAPEX incurred in Q1 | Over ₹200 cr |
| Planned CAPEX over FY23–FY24 | Close to ₹3,000 cr |
| First long-term contract utilization | ~25% in Q1; full-year FY23 expected 30–40%, H2 around 50% |
| Second long-term contract utilization | ~40% in Q1 |
| Nitrochlorobenzene production | 20,515 MT for the quarter |
| Nitrotoluene production | 5,252 MT for the quarter |
| PDA volumes | ~370 tons per month |
| Value-added products share in Specialty Chemicals | 74% |
| USFDA audit at Dombivli API unit | 2 observations under Form 483 |